Literature DB >> 29563344

Chromosomal inversions as a hidden disease-modifying factor for somatic recombination phenotypes.

Toshifumi Nomura1, Shotaro Suzuki1, Toshinari Miyauchi1, Masae Takeda1, Satoru Shinkuma1, Yasuyuki Fujita1, Wataru Nishie1, Masashi Akiyama2, Hiroshi Shimizu1.   

Abstract

Heterozygous chromosomal inversions suppress recombination. Therefore, they may potentially influence recombination-associated phenotypes of human diseases, but no studies have verified this hypothesis. Here, we describe a 35-year-old man with severe congenital ichthyosis. Mutation analysis revealed a heterozygous splice-site mutation, c.1374-2A>G (p.Ser458Argfs*120), in KRT10 on 17q21.2. This mutation was previously reported in patients with ichthyosis with confetti type I (IWC-I), a prominent skin disease characterized by the frequent occurrence of recombination-induced reversion of pathogenic mutations. Intriguingly, the number of revertant skin areas in this patient is considerably reduced compared with typical IWC-I cases. G-banded karyotyping revealed that the patient harbors a heterozygous nonpathogenic inversion, inv(17)(p13q12), whose long-arm breakpoint was subsequently refined to chromosomal positions (chr17: 36,544,407-36,639,830) via FISH. Collectively, the only chance of revertant mosaicism through somatic recombination appears to involve recombination between the KRT10 mutation and the inversion breakpoint. Indeed, in the examined revertant spot, the KRT10 mutation was diminished by somatic recombination starting from chromosomal positions (chr17: 36,915,505-37,060,285) on 17q12. This study provides the first evidence to our knowledge implicating chromosomal inversions as a potential modifier of clinical phenotypes. Furthermore, the reduced occurrence of revertant spots in the recombination-suppressed patient suggests that somatic recombination is the main mechanism of revertant mosaicism in IWC-I.

Entities:  

Keywords:  Dermatology; Genetic diseases; Genetics; Skin

Mesh:

Substances:

Year:  2018        PMID: 29563344      PMCID: PMC5926924          DOI: 10.1172/jci.insight.97595

Source DB:  PubMed          Journal:  JCI Insight        ISSN: 2379-3708


  20 in total

1.  Revertant somatic mosaicism by mitotic recombination in dyskeratosis congenita.

Authors:  Marjolijn C J Jongmans; Eugene T P Verwiel; Yvonne Heijdra; Tom Vulliamy; Eveline J Kamping; Jayne Y Hehir-Kwa; Ernie M H F Bongers; Rolph Pfundt; Liesbeth van Emst; Frank N van Leeuwen; Koen L I van Gassen; Ad Geurts van Kessel; Inderjeet Dokal; Nicoline Hoogerbrugge; Marjolijn J L Ligtenberg; Roland P Kuiper
Journal:  Am J Hum Genet       Date:  2012-02-16       Impact factor: 11.025

Review 2.  Revertant mosaicism in skin: natural gene therapy.

Authors:  Joey E Lai-Cheong; John A McGrath; Jouni Uitto
Journal:  Trends Mol Med       Date:  2010-12-29       Impact factor: 11.951

3.  Revertant mosaicism--patchwork in the skin.

Authors:  Marcel F Jonkman; Anna M G Pasmooij
Journal:  N Engl J Med       Date:  2009-04-16       Impact factor: 91.245

4.  Revertant Mosaicism in Ichthyosis with Confetti Caused by a Frameshift Mutation in KRT1.

Authors:  Shotaro Suzuki; Toshifumi Nomura; Toshinari Miyauchi; Masae Takeda; Hideki Nakamura; Satoru Shinkuma; Yasuyuki Fujita; Masashi Akiyama; Hiroshi Shimizu
Journal:  J Invest Dermatol       Date:  2016-06-07       Impact factor: 8.551

5.  A patient-derived-xenograft platform to study BRCA-deficient ovarian cancers.

Authors:  Erin George; Hyoung Kim; Clemens Krepler; Brandon Wenz; Mehran Makvandi; Janos L Tanyi; Eric Brown; Rugang Zhang; Patricia Brafford; Stephanie Jean; Robert H Mach; Yiling Lu; Gordon B Mills; Meenhard Herlyn; Mark Morgan; Xiaochen Zhang; Robert Soslow; Ronny Drapkin; Neil Johnson; Ying Zheng; George Cotsarelis; Katherine L Nathanson; Fiona Simpkins
Journal:  JCI Insight       Date:  2017-01-12

6.  Frequent somatic reversion of KRT1 mutations in ichthyosis with confetti.

Authors:  Keith A Choate; Yin Lu; Jing Zhou; Peter M Elias; Samir Zaidi; Amy S Paller; Anita Farhi; Carol Nelson-Williams; Debra Crumrine; Leonard M Milstone; Richard P Lifton
Journal:  J Clin Invest       Date:  2015-03-16       Impact factor: 14.808

Review 7.  The molecular underpinnings of prostate cancer: impacts on management and pathology practice.

Authors:  Daniel Nava Rodrigues; Gunther Boysen; Semini Sumanasuriya; George Seed; Angelo M De Marzo; Johann de Bono
Journal:  J Pathol       Date:  2016-12-01       Impact factor: 7.996

8.  A Robertsonian translocation suppresses a somatic recombination pathway to loss of heterozygosity.

Authors:  Kevin M Haigis; William F Dove
Journal:  Nat Genet       Date:  2002-11-25       Impact factor: 38.330

9.  Expanding the Clinical and Genetic Spectrum of KRT1, KRT2 and KRT10 Mutations in Keratinopathic Ichthyosis.

Authors:  Alrun Hotz; Vinzenz Oji; Emmanuelle Bourrat; Nathalie Jonca; Juliette Mazereeuw-Hautier; Regina C Betz; Ulrike Blume-Peytavi; Karola Stieler; Fanny Morice-Picard; Ines Schönbuchner; Susanne Markus; Nina Schlipf; Judith Fischer
Journal:  Acta Derm Venereol       Date:  2016-05       Impact factor: 4.437

10.  Somatic intragenic recombination within the mutated locus BLM can correct the high sister-chromatid exchange phenotype of Bloom syndrome cells.

Authors:  N A Ellis; D J Lennon; M Proytcheva; B Alhadeff; E E Henderson; J German
Journal:  Am J Hum Genet       Date:  1995-11       Impact factor: 11.025

View more
  3 in total

1.  Revertant mosaic fibroblasts in recessive dystrophic epidermolysis bullosa.

Authors:  K Twaroski; C Eide; M J Riddle; L Xia; C J Lees; W Chen; W Mathews; D R Keene; J A McGrath; J Tolar
Journal:  Br J Dermatol       Date:  2019-07-08       Impact factor: 9.302

2.  Somatic recombination underlies frequent revertant mosaicism in loricrin keratoderma.

Authors:  Shotaro Suzuki; Toshifumi Nomura; Toshinari Miyauchi; Masae Takeda; Yasuyuki Fujita; Wataru Nishie; Masashi Akiyama; Akemi Ishida-Yamamoto; Hiroshi Shimizu
Journal:  Life Sci Alliance       Date:  2019-02-04

3.  Common polymorphic inversions at 17q21.31 and 8p23.1 associate with cancer prognosis.

Authors:  Carlos Ruiz-Arenas; Alejandro Cáceres; Victor Moreno; Juan R González
Journal:  Hum Genomics       Date:  2019-11-21       Impact factor: 4.639

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.